ES2377337T3 - Derivados pirimidina y su uso como antogonistas del receptor P2Y12 - Google Patents
Derivados pirimidina y su uso como antogonistas del receptor P2Y12 Download PDFInfo
- Publication number
- ES2377337T3 ES2377337T3 ES06728064T ES06728064T ES2377337T3 ES 2377337 T3 ES2377337 T3 ES 2377337T3 ES 06728064 T ES06728064 T ES 06728064T ES 06728064 T ES06728064 T ES 06728064T ES 2377337 T3 ES2377337 T3 ES 2377337T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- hydrogen
- aryl
- heterocyclic ring
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto seleccionado del grupo que consiste en los compuestos de fórmula I en la cual R1 representa fenilo opcionalmente sustituido de 1 a 3 veces por sustituyentes cada uno independientemente seleccionado del grupo que consiste en halógeno, metilo, metoxi, trifluorometilo y trifluorometoxi; W representa un enlace, y R2 representa alquilo, haloalquilo, ciano, hidroxialquilo, hidroxialquilo sustituido en su cadena alquílica con un grupo fenilo no sustituido, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, o uno de los radicales en los cuales m es 0 y n es 2 ó 3, o m es 1 y n es 2, p es 0 y q es 2 ó 3, o p es 1 y q es 2, o también p es 2 ó 3 y q es 0, Q es -CO- o -CH(ORa)-, siendo Ra hidrógeno o alquilo, y Q' es -CO-; o W representa -CH2- y R2 representa -NR7R8, -SR9 o -SO2R10; W representa -O- o -S- y R2 representa alquilo, carboxialquilo, alcoxicarbonilalquilo, hidroxialquilo, alcoxialquilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo o heteroarilalquilo; W representa -NR3- y R2 representa hidrógeno, alquilo, dialquilaminoalquilo, alcoxicarbonilalquilo, carboxialquilo, carboxialquilo sustituido en su sección alquilo con un grupo fenilo no sustituido, hidroxialquilo, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, 2-fenilciclopropilo, aralquilo, difenilalquilo, heteroarilalquilo en donde el heteroarilo es un heteroarilo monocíclico, -COR11 ó -SO2R12; W representa -CH=CH- y R2 representa alquilo, hidroxialquilo, alcoxialquilo, alcoxicarbonilo, fenilo o -CO-NR13R14; o W representa -CºC- y R2 representa hidrógeno, alquilo, hidroxialquilo o alcoxialquilo; o W representa -CO- y R2 representa alquilo; R3 representa hidrógeno o alquilo; R7 representa alquilo o arilalquilo; R8 representa alquilo; o R7 y R8 forman, en conjunto con el nitrógeno que los porta, un anillo heterocíclico de 4 a 7 elementos en el cual los elementos que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera 5 independiente de entre -CH2-, -CH(CH3)-, -CHRy-, -O-, -S-, -CO- y -NRz-, entendiéndose sin embargo que dicho anillo heterocíclico no contiene más que un elemento seleccionado del grupo que consiste en -CHRy-, -O-, -S-, -CO- y -NRz-, representando Ry hidroxi, hidroximetilo, alcoximetilo, alcoxicarbonilo o alcoxi y representando Rz hidrógeno, alquilo o alcoxicarbonilo; R9 representa cicloalquilo o arilo; R10 representa alquilo, cicloalquilo o arilo; R11 representa alquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo monocíclico o aralquilo; R12 representa alquilo o arilo; R13 representa alquilo; R14 representa alquilo; o W representa -NR3- y R2 y R3 forman, en conjunto con el nitrógeno que los porta, un anillo heterocíclico de 4 a 7 elementos en el cual los elementos que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -CHRx-, -O-, -S-, -CO- y -NR4-, y entendiéndose que dicho anillo heterocíclico no contiene más que un elemento seleccionado del grupo que consiste en -CHRx-, -O-, -S-, -CO- y -NR4-, representando Rx hidroxi, hidroximetilo, alcoximetilo o alcoxi y R4 20 representando hidrógeno o alquilo; o también W representa -NR3- y R2 y R3 forman, en conjunto con el nitrógeno que los porta, bien un anillo imidazolilo, pirazolilo, 1,2,3-triazolilo o 1,2,4-triazolilo, anillo que puede estar sustituido con un grupo alquilo, o un anillo 4-oxo-4H-piridin-1-ilo, 4,5-dihidro-pirazol-1-ilo, 2-metil-4,5-dihidro-imidazol-1-ilo o 3-metil-5-oxo-2,5- dihidro-pirazol-1-ilo; cada uno de R5a y R5b representa, de manera independiente, hidrógeno o metilo; X representa -CO- y R6 representa alquilo, cicloalquilo, alcoxi, alquiniloxi, ariloxi, aralcoxi, arilo, heteroarilo monocíclico, aralquilo o NR15R16, o X representa -SO2- y R6 representa alquilo; R15 representa alquilo; R16 representa hidrógeno o alquilo; o R15 y R16 forman, en conjunto con el nitrógeno que los porta, un anillo heterocíclico de 4 a 7 elementos, en el cual los elementos que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -O-, -S- y -NRw-, representando Rw hidrógeno o alquilo, entendiéndose que dicho anillo heterocíclico no contiene más que un elemento del grupo que consiste en -O-, -S- y -NRw-; e Y representa un enlace y Z representa hidrógeno o arilo sustituido por carboxialcoxi; o Y representa alquileno, alcoxialquileno, fenilalquileno, alcoxifenileno o alcoxifenilalquileno y Z representa hidrógeno, -OH, -NH2, -COOH, tetrazolilo, -CO-NH2, -COOR17, -NH-CO-R17, -NH-COOR17 o -NH-SO2-R17, representando R17 alquilo; y un enantiómero ópticamente puro, una mezcla de enantiómeros, un racemato, un diastereoisómero ópticamente puro, una mezcla de diastereoisómeros, un racemato diastereoisomérico, una mezcla de racematos diastereoisoméricos, una meso forma, una sal, un complejo disuelto, o una forma morfológica del mismo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2005004578 | 2005-04-28 | ||
WOPCT/EP2005/004578 | 2005-04-28 | ||
IB2005053711 | 2005-11-10 | ||
WOPCT/IB2005/053711 | 2005-11-10 | ||
PCT/IB2006/051318 WO2006114774A2 (en) | 2005-04-28 | 2006-04-27 | Pyrimidine derivatives and their use as p2y12 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2377337T3 true ES2377337T3 (es) | 2012-03-26 |
Family
ID=37075078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06728064T Active ES2377337T3 (es) | 2005-04-28 | 2006-04-27 | Derivados pirimidina y su uso como antogonistas del receptor P2Y12 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8048881B2 (es) |
EP (1) | EP1893634B1 (es) |
JP (1) | JP4955658B2 (es) |
KR (1) | KR101310016B1 (es) |
CN (1) | CN101166756A (es) |
AR (1) | AR056992A1 (es) |
AT (1) | ATE538130T1 (es) |
AU (1) | AU2006241260A1 (es) |
BR (1) | BRPI0608089A2 (es) |
CA (1) | CA2604967C (es) |
ES (1) | ES2377337T3 (es) |
IL (1) | IL186939A0 (es) |
MX (1) | MX2007013436A (es) |
NO (1) | NO20076094L (es) |
NZ (1) | NZ563584A (es) |
RU (1) | RU2410393C2 (es) |
TW (1) | TW200640877A (es) |
WO (1) | WO2006114774A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210635A1 (en) * | 2006-03-29 | 2010-08-19 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
CL2007003038A1 (es) * | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
EP2148871A1 (en) * | 2007-04-23 | 2010-02-03 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
BRPI0819696B1 (pt) * | 2007-11-29 | 2018-10-23 | Actelion Pharmaceuticals Ltd | compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto |
EP2238127B1 (en) * | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
JP5504171B2 (ja) * | 2007-12-26 | 2014-05-28 | サノフイ | P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
MX2010009561A (es) | 2008-02-29 | 2010-09-24 | Renovis Inc | Compuestos amida, composiciones y usos de los mismos. |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
AR071653A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
WO2009131127A1 (ja) * | 2008-04-22 | 2009-10-29 | 第一三共株式会社 | 5-ヒドロキシピリミジン-4-カルボキサミド化合物 |
US20110237578A1 (en) * | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
KR101114503B1 (ko) * | 2008-12-04 | 2012-02-15 | 지에스건설 주식회사 | 부유물 수거장치 |
MA33260B1 (fr) * | 2009-04-08 | 2012-05-02 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines |
KR101728180B1 (ko) * | 2009-04-22 | 2017-04-18 | 액테리온 파마슈티칼 리미티드 | 티아졸 유도체들 및 p2y12 수용체 길항제로서 이들의 용도 |
JP5597202B2 (ja) | 2009-08-28 | 2014-10-01 | 第一三共株式会社 | 3−(ビアリールオキシ)プロピオン酸誘導体 |
US9539246B2 (en) | 2011-08-30 | 2017-01-10 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
ES2643235T3 (es) * | 2011-09-02 | 2017-11-21 | Purdue Pharma Lp | Pirimidinas como bloqueantes del canal de sodio |
RS62946B1 (sr) | 2016-09-22 | 2022-03-31 | Idorsia Pharmaceuticals Ltd | Kristalni oblici |
AU2018234056B2 (en) | 2017-03-15 | 2023-05-25 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
CN112500354A (zh) * | 2020-12-08 | 2021-03-16 | 烟台凯博医药科技有限公司 | 一种4-氯-6-环丙基嘧啶-5-胺的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373586A (en) * | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
DE60333866D1 (de) * | 2002-12-11 | 2010-09-30 | Bayer Schering Pharma Ag | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten |
CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
BRPI0819696B1 (pt) | 2007-11-29 | 2018-10-23 | Actelion Pharmaceuticals Ltd | compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
MA33260B1 (fr) | 2009-04-08 | 2012-05-02 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines |
KR101728180B1 (ko) | 2009-04-22 | 2017-04-18 | 액테리온 파마슈티칼 리미티드 | 티아졸 유도체들 및 p2y12 수용체 길항제로서 이들의 용도 |
-
2006
- 2006-04-25 TW TW095114722A patent/TW200640877A/zh unknown
- 2006-04-26 AR ARP060101670A patent/AR056992A1/es not_active Application Discontinuation
- 2006-04-27 AT AT06728064T patent/ATE538130T1/de active
- 2006-04-27 CN CNA2006800143742A patent/CN101166756A/zh active Pending
- 2006-04-27 NZ NZ563584A patent/NZ563584A/en unknown
- 2006-04-27 RU RU2007143880/04A patent/RU2410393C2/ru not_active IP Right Cessation
- 2006-04-27 JP JP2008508400A patent/JP4955658B2/ja active Active
- 2006-04-27 CA CA2604967A patent/CA2604967C/en active Active
- 2006-04-27 EP EP06728064A patent/EP1893634B1/en active Active
- 2006-04-27 AU AU2006241260A patent/AU2006241260A1/en not_active Withdrawn
- 2006-04-27 WO PCT/IB2006/051318 patent/WO2006114774A2/en active Application Filing
- 2006-04-27 BR BRPI0608089-8A patent/BRPI0608089A2/pt not_active IP Right Cessation
- 2006-04-27 ES ES06728064T patent/ES2377337T3/es active Active
- 2006-04-27 MX MX2007013436A patent/MX2007013436A/es active IP Right Grant
- 2006-04-27 KR KR1020077026652A patent/KR101310016B1/ko active IP Right Grant
- 2006-04-27 US US11/912,545 patent/US8048881B2/en active Active
-
2007
- 2007-10-25 IL IL186939A patent/IL186939A0/en unknown
- 2007-11-27 NO NO20076094A patent/NO20076094L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200640877A (en) | 2006-12-01 |
RU2007143880A (ru) | 2009-06-10 |
BRPI0608089A2 (pt) | 2009-11-10 |
MX2007013436A (es) | 2008-01-16 |
KR101310016B1 (ko) | 2013-09-30 |
NZ563584A (en) | 2011-03-31 |
JP2008539224A (ja) | 2008-11-13 |
AR056992A1 (es) | 2007-11-07 |
US20080194576A1 (en) | 2008-08-14 |
JP4955658B2 (ja) | 2012-06-20 |
ATE538130T1 (de) | 2012-01-15 |
RU2410393C2 (ru) | 2011-01-27 |
CN101166756A (zh) | 2008-04-23 |
AU2006241260A1 (en) | 2006-11-02 |
WO2006114774A2 (en) | 2006-11-02 |
EP1893634A2 (en) | 2008-03-05 |
CA2604967A1 (en) | 2006-11-02 |
IL186939A0 (en) | 2008-02-09 |
EP1893634B1 (en) | 2011-12-21 |
WO2006114774A3 (en) | 2007-02-08 |
KR20080004608A (ko) | 2008-01-09 |
CA2604967C (en) | 2014-04-01 |
US8048881B2 (en) | 2011-11-01 |
NO20076094L (no) | 2008-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2377337T3 (es) | Derivados pirimidina y su uso como antogonistas del receptor P2Y12 | |
AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
ES2564782T3 (es) | Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos | |
AR047533A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
ES2452299T3 (es) | Compuestos heterocíclicos fungicidas | |
AR075858A1 (es) | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa | |
AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
PE20121127A1 (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteina | |
AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
PE20060600A1 (es) | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa | |
AR064824A1 (es) | Derivados de espirocromanona sustituidos | |
CO5601029A2 (es) | Inhibidores no nucleosidos de transcriptasa inversa i para el tratamiento de enfermedades mediadas por vih | |
CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
CR10346A (es) | Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 | |
WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP |